



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/891,671	06/26/2001	Derek A. Pratt	N-6636	9766
5	7590 03/06/2003			
STITES & HARBISON 424 CHURCH STREET SUITE 1800			EXAMINER	
			TRUONG, TAMTHOM NGO	
NASHVILLE, TN 37219			ART UNIT	PAPER NUMBER
			1624	

DATE MAILED: 03/06/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

			•				
\$		Application N .	Applicant(s)				
Office Action Summary		09/891,671	PRATT ET AL.				
		Examiner	Art Unit				
		Tamthom N. Truong	1624				
The MAILING DATE of this communication appears n the cover sheet with the corresp ndence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status							
1)🖂	Responsive to communication(s) filed on 23 L	December 2002 .					
2a)□	This action is FINAL . 2b)⊠ Th	is action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
	Claim(s) <u>32-50</u> is/are pending in the application.						
	4a) Of the above claim(s) is/are withdrawn from consideration.						
·	5) Claim(s) is/are allowed.						
_	6) Claim(s) 32,35-37,41,43, 49 and 50 is/are rejected.						
7) Claim(s) 33, 34, 38-40, 42, and 44-48 is/are objected to.							
8) Claim(s) are subject to restriction and/or election requirement. Application Papers							
9) The specification is objected to by the Examiner.							
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12)☐ The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) All b) Some * c) None of:							
1. Certified copies of the priority documents have been received.							
	2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.							
14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
2) Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s) <u>5.</u> 0	5) Notice of Informal F	v (PTO-413) Paper No(s) Patent Application (PTO-152)				

Application/Control Number: 09/891,671

Art Unit: 1624

DETAILED ACTION

Applicant's amendment of 12-23-02 has been considered. Applicant's affirmation of group I (drawn to the subject matter of formulae 4, 7, and 9) is also acknowledged. Original claims 1-31 have been cancelled, thus the previous rejections have been obviated. New claims 32-50 are drawn to the elected group I. Thus, the following office action is based on said claims.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

- 1. Claims 35-37, and 43 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The following reasons apply:
 - a. Claim 35 lacks antecedent basis because it recites R₂ as "alkoxy, amino, N-alkylamino and N,N-dialkylamino" which is not as recited in claim 32.
 - b. Claims 36 and 37 are improper multiple dependent claims because they depend on both claim 1 (which has been cancelled), and claim 32.
 - c. Claim 43 lacks antecedent basis because it recites a species of "5-pyrimidinol" which is not encompassed by formula 4 in claim 32. Note, R₃ must be an "electron donating substituent", and not a hydrogen.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

Application/Control Number: 09/891,671

Art Unit: 1624

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

2. **New Matter:** Claim 35 is rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The specification does not provide support for compounds of formula 4 with R₂ as "alkoxy, amino, N-alkylamino and N,N-dialkylamino".

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

- (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 3. Claims 32, 36, 41, 49 and 50 are rejected under 35 U.S.C. 103(a) as being unpatentable over **Belliotti et. al.** (US 5,284,949 cited on IDS). On column 4, lines 35-45, Belliotti et. al. discloses compounds that are embraced by the claimed formulae 4 and 7 with R₁ and R₂ as alkyl groups while R₃ is an electron donating group or an amino group. Belliotti et. al. use their compounds as inhibitors of cyclooxygenase, which is not the claimed method. However,

Application/Control Number: 09/891,671

Art Unit: 1624

Belliotti et. al. acknowledge that their compounds "also have potential utility as antioxidants"

(see column 1, line 35). Although no specific guidance is provided, the mere recognition of

substituted pyrimidinol compounds as antioxidants would have motivated one skilled in the art to

select compounds of formulae 4 and 7 to inhibit oxidation. Thus, at the time of the invention, it

would have been obvious to one of the ordinary skill in the art to develop the claimed method in

view of the teaching of Belliotti et. al.

Claim Objections

4. Claims 33, 34, 38-40, 42, and 44-48 are objected to as being dependent upon a rejected

base claim, but would be allowable if rewritten in independent form including all of the

limitations of the base claim and any intervening claims.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tamthom N. Truong whose telephone number is 703-305-4485.

The examiner can normally be reached on M-F (9:00-5:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mukund Shah can be reached on 703-308-4716. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4556 for regular

communications and 703-308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding

should be directed to the receptionist whose telephone number is 703-308-1235.

Tamthom N. Truong

Page 4

Examiner

Art Unit 1624
